SCHEMBL26337490

SCHEMBL26337490

c1ccc(-c2ccc3cc(N(c4ccc(-c5ccc6c(ccc7ccccc76)c5)cc4)c4cccc(-c5ccc6c(c5)c(-c5ccccc5)c(-c5ccccc5)c5ccccc56)c4)ccc3c2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 6/20 0.39
ESR2 Q92731 6/20 0.39
HSD17B1 P14061 5/20 0.39
HSD17B2 P37059 5/20 0.39
CYP1A2 P05177 4/20 0.39
CYP3A4 P08684 2/20 0.39
CYP2D6 P10635 2/20 0.39
CYP2C9 P11712 2/20 0.39
CYP2B6 P20813 2/20 0.39
CYP2C19 P33261 2/20 0.39
HPRT1 P00492 1/20 0.34
GPR84 Q9NQS5 1/20 0.34
CYP1B1 Q16678 2/20 0.33
CYP1A1 P04798 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HIF1A Q16665 1/20 0.33
HSD17B10 Q99714 1/20 0.33
SOS1 Q07889 1/20 0.32
CDK4 P11802 1/20 0.32
CCND1 P24385 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26339914 0.99 ESR1 (0.39) ESR1ESR2HSD17B1HSD17B2CYP1A2
SCHEMBL26337499 0.99 ESR1 (0.39) ESR1ESR2HSD17B1HSD17B2CYP1A2
SCHEMBL26337487 0.99 ESR1 (0.39) ESR1ESR2HSD17B1HSD17B2CYP1A2
SCHEMBL26337567 0.99 ESR1 (0.39) ESR1ESR2HSD17B1HSD17B2CYP1A2
SCHEMBL26337395 0.99 ESR1 (0.40) ESR1ESR2HSD17B1HSD17B2CYP1A2
SCHEMBL26337479 0.99 ESR1 (0.40) ESR1ESR2HSD17B1HSD17B2CYP1A2
SCHEMBL26337483 0.98 ESR1 (0.39) ESR1ESR2HSD17B1HSD17B2CYP1A2
SCHEMBL26337491 0.98 ESR1 (0.39) ESR1ESR2HSD17B1HSD17B2CYP1A2
SCHEMBL26339956 0.98 ESR1 (0.39) ESR1ESR2HSD17B1HSD17B2CYP1A2
SCHEMBL26339884 0.96 ESR1 (0.42) ESR1ESR2HSD17B1HSD17B2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230301176-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE ELEMENTS, ORGANIC ELECTROLUMINESCENCE ELEMENT, AND ELECTRONIC DEVICE IDEMITSU KOSAN CO.,LTD. (JP) 2023-09-21 US disclosed
US-20230301176-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE ELEMENTS, ORGANIC ELECTROLUMINESCENCE ELEMENT, AND ELECTRONIC DEVICE IDEMITSU KOSAN CO.,LTD. (JP) 2023-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230301176-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE ELEMENTS, ORGANIC ELECTROLUMINESCENCE ELEMENT, AND ELECTRONIC DEVICE LEF1, ELAVL1, PIEZO1 ESR1 74/4885ESR2 419/4885HSD17B1 2697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.